´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ 1Ãþ À¯ÀÏÇÑȦ
±³À°ÁÖÁ¦ : KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÁö¹æ°£¿¬±¸È¸
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í "»çÀüµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 3¸¸¿ø
ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 4¸¸¿ø
ÇöÀåµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 4¸¸¿ø
ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 5¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:15~09:35 NAFLD and type 2 diabetes ÇÑÀ¯Áø(°è¸íÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:35~09:55 NAFLD and chronic kidney disease Á¤Âù¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:55~10:15 Identification of NAFLD patients with high-risk CVD ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:15~10:35 NAFLD and obesity: Medical perspective Alice PS KONG(CUHK)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:45~11:05 Sex-dependent NAFLD progression Ayako Suzuki(Duke University)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:05~11:25 Cognitive and behavioral impairments related to NASH Somaya Albhaisi(Virginia Commonwealth University)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:25~11:45 Role of hepatocyte Kctd17 in glucose tolerance and hepatic steatosis ±è°æÁø(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:45~12:05 Tcf7l2 in hepatocytes regulates de novo lipogenesis in NAFLD ¿À°æÁø(KRIBB)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 12:05~12:25 Roles of portal lipoprotein and immunity as guardians of the liver ÇÑ¿ëÇö(°¿ø¾à´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:25~13:45 Barriers for successful clinical trials in NASH Stephen A Harrison(Pinnacle Clinical Research, San Antonio)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:45~14:05 Biomarkers for identifying at-risk NASH and monitoring treatment response ±è¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:05~14:25 Pharmacotherapeutics in phase II and III clinical trial ¹Ú¼ö¿µ(°æºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:35~14:55 Different diets, different outcomes °íÇýÁø(°æºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:55~15:15 What types of exercise are beneficial for NAFLD/NASH? ¹ÚÁøÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:15~15:35 The potential of 3D food printing technology for application to patients with metabolic diseases ±èÀº°æ(µ¿¾Æ´ëÇб³)
±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:35~15:55 Novel therapeutic targets in NAFLD treatment in the year of 2023 Àü´ë¿ø(ÇѾçÀÇ´ë)